Artificial organs最新文献

{"title":"Continuous Blood Gas Control Based on Active Disturbance Rejection Control During Ex Vivo Porcine Liver Perfusion.","authors":"Yilong Zhao, Xin Lyu, Zhen Sun, Xiaoliang Zhang, Jin Cen, Tianhang Yang, Xiaoliang Xu, Wenhui Xing, Sihan Zhao, Bidou Wang, Gangyin Luo","doi":"10.1111/aor.14955","DOIUrl":"https://doi.org/10.1111/aor.14955","url":null,"abstract":"<p><strong>Background: </strong>Membrane oxygenators facilitate extracorporeal gas exchange, necessitating the monitoring of blood gas. Recent advances in normothermic machine perfusion (NMP) for ex vivo liver offer solutions to the shortage of donor liver. However, maintaining physiological blood gas levels during prolonged NMP is complex and costly.</p><p><strong>Methods: </strong>We introduce a noninvasive and economical approach for regulating the blood gas during NMP of ex vivo porcine livers. By monitoring gas fractions at the outlet of oxygenator, real-time adjustments of blood gas can be made without the online blood gas analyzer. The method involves constructing multivariate linear regression (MLR) models, aligning target setpoints of gas, and employing active disturbance rejection control (ADRC) to achieve closed-loop regulation.</p><p><strong>Results: </strong>Ex vivo porcine liver perfusion experiments demonstrated the effectiveness of the method, maintaining blood gas within physiological levels over 24 h (oxygen partial pressure: 150.36 ± 3.33 mmHg, carbon dioxide partial pressure: 41.34 ± 0.91 mmHg).</p><p><strong>Conclusion: </strong>ADRC-based continuous regulation of gas fraction at the outlet of oxygenator is a feasible and effective approach for managing blood gas during ex vivo porcine liver perfusion.</p>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Cannulation Strategy and Extracorporeal Blood Flow on Recirculation During Veno-Venous Extracorporeal Membrane Oxygenation.","authors":"Jan-Steffen Pooth, Jil Kristin Förster, Christoph Benk, Patric Diel, Sam Joé Brixius, Sven Maier, Alexander Supady, Tobias Wengenmayer, Dawid Leander Staudacher, Gerd-Walter Haimerl, Martin Czerny, Julia Benk","doi":"10.1111/aor.14961","DOIUrl":"https://doi.org/10.1111/aor.14961","url":null,"abstract":"<p><strong>Introduction: </strong>Veno-venous extracorporeal membrane oxygenation (V-V ECMO) is increasingly used in the treatment of severe respiratory failure. Despite a significant increase in the worldwide use of extracorporeal lung assist devices recirculation remains a common complication and is associated with a reduced effectiveness of ECMO support and increased hemolysis. In this observational study we aimed to investigate the impact of cannula configuration and extracorporeal flow on recirculation.</p><p><strong>Materials and methods: </strong>An observational retrospective study was performed, which included all patients, who received V-V ECMO and recirculation measurements at the University Medical Center Freiburg between August 2021 and June 2023. Recirculation and extracorporeal flow were determined using ultrasonic indicator dilution technology. Patients were divided into subgroups according to their type of cannulation (dual lumen single-site vs. bifemoral vs. femoro-jugular).</p><p><strong>Results: </strong>A total of 215 recirculation measurements in 47 patients were performed. Dual lumen single-site cannulation was associated with significantly lower recirculation rates (8.7% [0.0; 12.0]) compared to single lumen dual-site cannulation (femoro-jugular: 17.6% [0.0; 25.8]; bifemoral: 27.9% ± 13.4%). In addition, a positive linear correlation was observed between extracorporeal flow and recirculation in all subgroups. Recirculation increased significantly with rising extracorporeal flow in all subgroups.</p><p><strong>Conclusion: </strong>Recirculation is a common complication in V-V ECMO and can lead to a reduction of ECMO effectiveness. Particular attention should be paid to optimal positioning of the cannulas in patients with more than one cannula. The ultrasonic indicator dilution method is a simple and quick method for measuring recirculation in V-V ECMO and can be used at an early stage if effectiveness decreases.</p>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short (2-Hour) Non-Oxygenated End-Ischemic Hypothermic Perfusion Versus Cold Storage in the Setting of Renal Transplantation.","authors":"Franco Ruberto, Quirino Lai, Mario Piazzolla, Luca Poli, Veronica Zullino, Giulia Diamantini, Matteo Brisciani, Francesco Giovanardi, Fabio Melandro, Silvia Quaresima, Massimo Rossi, Manuela Garofalo, Francesco Pugliese","doi":"10.1111/aor.14953","DOIUrl":"https://doi.org/10.1111/aor.14953","url":null,"abstract":"<p><strong>Background: </strong>Kidney transplantation (KT) is the most effective treatment for end-stage renal disease. End-ischemic hypothermic machine perfusion (EI-HMP) has emerged as a promising method for preserving grafts before transplantation. This study aimed to compare graft function recovery in KT recipients of deceased brain-death (DBD) grafts preserved with EI-HMP versus static cold storage (SCS). The primary outcome was the rate of delayed graft function (DGF). Secondary outcomes included urine output, intensive care unit (ICU) stay, hospital stay duration, and survival rates.</p><p><strong>Methods: </strong>A retrospective, single-center observational study was conducted at Sapienza University of Rome, analyzing 313 KT patients between January 2014 and September 2021. Patients were stratified into two groups based on graft preservation methods (EI-HMP, n = 95; SCS, n = 218). A stabilized inverse probability treatment weighting (IPTW) method was employed to adjust for potential confounders.</p><p><strong>Results: </strong>There were no significant differences in DGF rates between the two groups (17.9% vs. 15.6% in SCS and EI-HMP cases, respectively; p = 0.75). EI-HMP group demonstrated a higher urine output on day 2 (p = 0.046), a shorter ICU stay (p < 0.0001), and a trend toward a shorter overall hospital stay (p = 0.07). No statistically significant differences were found between EI-HMP and SCS cases in 1- and 3-year overall survival rates (3.2% and 6.7% vs. 5.6% and 6.6%, respectively; log-rank p = 0.53) or in death-censored graft loss rates (5.4% and 8.9% vs. 5.7% and 7.3%, respectively; log-rank p = 0.88). In a sub-analysis of expanded criteria donors (ECD), EI-HMP demonstrated a protective effect by reducing the risk of DGF (OR = 0.31, 95% CI = 0.09-0.95; p = 0.047).</p><p><strong>Conclusion: </strong>EI-HMP was associated with certain short-term benefits, including increased urine output and reduced ICU stays, but showed no significant impact on long-term survival outcomes. A reduction in DGF rates was observed only in the ECD subgroup. Randomized controlled trials are necessary to further investigate the long-term clinical benefits of EI-HMP.</p>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143036304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Iodinated Contrast Adsorption in Cartridges With Styrene-Divinylbenzene Sorbent.","authors":"Thiago Reis, Gonzalo Ramírez-Guerrero, Roberto Pecoits-Filho, Anna Lorenzin, Massimo de Cal, Valentina Corradi, Gerd Klinkmann, Federico Ronco, Francisco A R Neves, Rinaldo Bellomo, Claudio Ronco","doi":"10.1111/aor.14949","DOIUrl":"https://doi.org/10.1111/aor.14949","url":null,"abstract":"<p><strong>Background: </strong>Contrast-associated acute kidney injury (CA-AKI) is frequent in patients with chronic kidney disease who are submitted to cardiac endovascular procedures using iodinated contrast. In hemoadsorption, cartridges containing styrene-divinylbenzene sorbent resin are applied to remove substances from the blood through an extracorporeal circuit. Importantly, iodinated contrast is also removed via adsorption. We aimed to determine the adsorptive kinetics of the iodinated contrast medium iohexol using a 1:3 scale model of the HA380 cartridge.</p><p><strong>Methods: </strong>An experimental in vitro study utilizing a closed-loop extracorporeal circuit with an interposed sorbent cartridge. A solution spiked with iohexol was recirculated for 60 min. Samples for the measurement of iohexol were drawn at 0, 5, 10, 15, 20, 30, 40, and 60 min. The experiment was carried out twice.</p><p><strong>Results: </strong>In experiments 1 and 2, the reduction ratio after 60 min was 53.0% and 53.1%, respectively. In experiment 1, iohexol clearance was 46.79 mL/min during the first 5 min and decayed to 3.57 mL/min during the last 20 min. In experiment 2, iohexol clearance was 46.72 mL/min and decayed to 3.87 mL/min during the last 20 min. The ratio of adsorbate/sorbent was 155 mg/g.</p><p><strong>Conclusion: </strong>A 1:3 scale model of the HA380 cartridge efficiently removes iodinated contrast in a clinical-scale in vitro circuit. These findings provide a rationale for hemoadsorption as an intervention in clinical trials to prevent or attenuate CA-AKI.</p>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143031886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recreating the Endocrine Niche: Advances in Bioengineering the Pancreas","authors":"Laura Mar Fonseca,&nbsp;Nicerine Krause,&nbsp;Fanny Lebreton,&nbsp;Ekaterine Berishvili","doi":"10.1111/aor.14950","DOIUrl":"10.1111/aor.14950","url":null,"abstract":"<div>\u0000 \u0000 <p>Intrahepatic islet transplantation is a promising strategy for β-cell replacement therapy in the treatment of Type 1 Diabetes. However, several obstacles hinder the long-term efficacy of this therapy. A major challenge is the scarcity of donor organs. During the isolation process, islets are disconnected from their extracellular matrix (ECM) and vasculature, leading to significant loss due to anoikis and hypoxia. Additionally, inflammatory and rejection reactions further compromise islet survival and engraftment success. Extensive efforts are being made to improve the efficacy of islet transplantation. These strategies include promoting revascularization and ECM support through bioengineering techniques, exploring alternative sources of insulin-secreting cells, and providing immunomodulation for the graft. Despite these advancements, a significant gap remains in integrating these strategies into a cohesive approach that effectively replicates the native endocrine environment. Specifically, the lack of comprehensive methods to address both the structural and functional aspects of the endocrine niche limits reproducibility and clinical translation. Therefore, bioengineering an endocrine pancreas must aim to recreate the endocrine niche to achieve lifelong efficacy and insulin independence. This review discusses various strategies developed to produce the building blocks for generating a vascularized, immune-protected insulin-secreting construct, emphasizing the importance of the endocrine niche's composition and function.</p>\u0000 </div>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":"49 4","pages":"541-555"},"PeriodicalIF":2.2,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143021723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Upcoming Meetings","authors":"","doi":"10.1111/aor.14944","DOIUrl":"https://doi.org/10.1111/aor.14944","url":null,"abstract":"","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":"49 2","pages":"332"},"PeriodicalIF":2.2,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143118009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glucagon-Like Peptide-1 Receptor Agonists in Patients With Durable Left Ventricular Assist Devices.","authors":"Boaz Elad, Changhee Lee, Afsana Rahman, Wojciech Rzechorzek, Ersilia M DeFilippis, Dor Lotan, Cathrine M Moeller, Andrea Fernandez Valledor, Salwa Rahman, Julia Baranowska, Kevin Clerkin, Justin Fried, Adil Yunis, Melana Yuzefpolskaya, Paolo C Colombo, Yuji Kaku, Yoshifumi Naka, Koji Takeda, Jayant Raikhelkar, Gabriel T Sayer, Nir Uriel","doi":"10.1111/aor.14942","DOIUrl":"https://doi.org/10.1111/aor.14942","url":null,"abstract":"<p><strong>Background: </strong>GLP-1 RAs improve cardiometabolic outcomes in obese, diabetic, and heart failure patients. Data on the safety and efficacy of GLP-1 RA in advanced heart failure with durable LVAD is limited.</p><p><strong>Objectives: </strong>To assess the safety and efficacy of GLP-1 RA in durable LVAD patients.</p><p><strong>Methods: </strong>We conducted a single-center retrospective analysis of patients on durable LVAD support treated with GLP-1 RA. Outcomes included cardiometabolic efficacy and LVAD and GLP-1 RA related adverse events up to 1 year post GLP-1 RA initiation.</p><p><strong>Results: </strong>Forty LVAD patients were treated with GLP-1 RA therapy between 2018 and 2023. At 1 year follow-up, the patient's weight was significantly reduced (116 (98-134) vs. 110 (91-129) kg, p-value < 0.001), HBA1C was improved (6.4 (5.8-8.1) vs. 5.7 (5.3-6.1), p-value 0.003), and NT-proBNP levels were significantly reduced (810 (594-1413) vs. 732 (354-1155) pg/mL, p-value 0.04). GLP-1 RA therapy was not associated with cannula position change (cannula coronal angle of 29.7° (15.0-42.0) vs. 23.1° (12.8-42.3), p-value 0.683), and LVADs complication rate was relatively low (12.5% of the patients had hemocompatibility adverse events, 15% had driveline infection, 12% had HF hospitalization, and 2.5% (1 patient) died due to HeartMate2 malfunction). There was no interruption of drug administration due to adverse events.</p><p><strong>Conclusion: </strong>Durable LVAD patients treated with GLP-1 RA had improved cardiometabolic profiles and low major adverse events. GLP-1 RA therapy holds promise as a potential adjunctive treatment strategy in LVAD recipients, offering improved cardiometabolic profile, hemodynamics, and potential future transplant candidacy.</p>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142999225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of HA130 Hemoadsorption in Removing Advanced Glycation End Products in Maintenance Hemodialysis Patients.","authors":"Gonzalo Ramírez-Guerrero, Thiago Reis, Barbara Segovia-Hernández, Francisca Aranda, Constanza Verdugo, Cristian Pedreros-Rosales, Matteo Marcello, Janina León, Armando Rojas, Francesco Galli, Claudio Ronco","doi":"10.1111/aor.14954","DOIUrl":"https://doi.org/10.1111/aor.14954","url":null,"abstract":"<p><strong>Background: </strong>Patients on maintenance hemodialysis (HD) face complications due to the accumulation of protein-bound uremic toxins, such as advanced glycation end products (AGEs), which contribute to inflammation, oxidative stress, and cardiovascular disease. Conventional HD techniques inadequately remove AGEs. This study evaluates the efficacy of the HA130 hemoadsorption cartridge combined with high-flux HD (HF-HD) in enhancing AGE removal.</p><p><strong>Methods: </strong>This prospective, single-center study included 20 maintenance HD patients randomized into two groups: HF-HD alone (n = 10) and HF-HD plus hemoadsorption (n = 10). Blood samples were collected before and after a single session to measure carboxymethyllysine (CML), soluble RAGE (sRAGE), prolactin, and parathyroid hormone (PTH) levels. Reduction ratios (RR) were calculated, including corrected for hemoconcentration (RRc), to ensure accuracy. Statistical analyses included Mann-Whitney U and Chi-square tests.</p><p><strong>Results: </strong>The HF-HD plus hemoadsorption group showed significantly enhanced removal of CML compared to HF-HD alone, with RRc of 64.7% [52.6-74.9] versus 39.3% [33.8-49.4], respectively (p = 0.045). Similarly, uncorrected reduction ratios demonstrated a trend favoring hemoadsorption, with values of 57.5% [45.1-70.7] versus 30.3% [19.1-44.5] (p = 0.053). Importantly, sRAGE levels were preserved in both groups (RRc: 23.4% (15.1-30.4) vs. 21.8% (16.6-31.7), p = 0.791), highlighting the safety of hemoadsorption. Other biochemical parameters, including prolactin, PTH, albumin, and electrolytes, showed no significant differences between groups. All sessions were completed without adverse events.</p><p><strong>Conclusion: </strong>Combining hemoadsorption with HF-HD significantly enhances CML removal, as evidenced by corrected RR, without compromising protective sRAGE levels. This innovative approach offers a promising adjunctive therapy for reducing AGEs-related complications in end-stage renal disease patients. Further longitudinal studies are needed to confirm these findings and evaluate long-term outcomes.</p>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142999223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Granulocyte and Monocyte Adsorption Therapy in Patients With Sepsis: A Feasibility Study.","authors":"Osamu Nishida, Tomoyuki Nakamura, Takaaki Nakada, Gaku Takahashi, Yoshiki Masuda, Hiroki Tsubouchi, Yasuyuki Kakihana, Yuichiro Sakamoto, Osamu Takasu, Hiroyuki Suzuki, Koichi Nakazawa, Iwao Kobayashi, Kent Doi, Sohta Uchiyama, Nobuya Kitamura, Toru Kotani, Naohide Kuriyama, Noriyuki Hattori, Yasushi Suzuki, Hiroomi Tatsumi, Kazuhiro Moriyama","doi":"10.1111/aor.14943","DOIUrl":"https://doi.org/10.1111/aor.14943","url":null,"abstract":"<p><strong>Background: </strong>The pathogenesis of sepsis is thought to be linked to a dysregulated immune response, particularly that involving neutrophils. We have developed a granulocyte adsorption column as a \"decoy organ,\" which relocates the massive inflammation in organs in the body to a blood purification column. This study was conducted to assess the safety and experimental effectiveness of granulocyte monocyte adsorption apheresis-direct hemoperfusion (G1-DHP) in the treatment of patients with sepsis, using a prospective, multicenter design.</p><p><strong>Methods: </strong>The study included patients diagnosed with sepsis and with an APACHE II score ranging from 17 to 34. A total of five G1-DHP were performed within 3 days of patient enrollment. The primary endpoint was the change in sequential organ failure assessment (SOFA) score from enrollment to 7 days, and the safety endpoints were adverse events and mortality at 28 days.</p><p><strong>Results: </strong>G1-DHP was performed on 82 patients. The median (interquartile range) SOFA score decreased from 10 (8-11) to 4 (3-7) after 7 days (n = 70; p < 0.01). Granulocytes, mainly neutrophils, were adsorbed, and the neutrophil-to-lymphocyte ratio significantly improved (p < 0.01). Notable improvements were observed in the SOFA scores for circulation and renal function. The acute physiology and chronic health evaluation II score of the 77 patients evaluated for mortality was 27, and the 28-day mortality rate was 7.8%.</p><p><strong>Conclusions: </strong>This study confirmed that G1-DHP can be safely used as an adjunct to standard sepsis treatment regimens. Although further investigations are required, G1-DHP is a promising supplemental therapy for sepsis.</p><p><strong>Trial registration: </strong>jRCT1080225183 (Japan Registry of Clinical Trials identifier).</p>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142999148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Highlights From the 2nd Turin International Workshop on Liver Machine Perfusion","authors":"Damiano Patrono,&nbsp;Nicola De Stefano,&nbsp;Rebecca Panconesi,&nbsp;Paulo N. Martins,&nbsp;Renato Romagnoli,&nbsp;Meeting Collaborators","doi":"10.1111/aor.14951","DOIUrl":"10.1111/aor.14951","url":null,"abstract":"<p>The 2nd Turin International Workshop on Liver Machine Perfusion took place in Turin, Italy, on November 22, 2024. Leading experts came together to discuss the current applications, limitations, and future directions of this technology, with a primary focus on but not limited to liver transplantation. This report provides a summary of the evidence, insights, and debates shared during the meeting.</p>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":"49 4","pages":"716-721"},"PeriodicalIF":2.2,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/aor.14951","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142999149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}